Pacific-4 Trial: Durvalumab Immunotherapy Versus Placebo With Stereotactic Body Radiation Therapy (Sbrt) In Early Stage, Unresected Non-Small Cell Lung Cancer Patients
Posted Date: Sep 28, 2020
- Investigator: Emily Daugherty
- Specialties: Cancer, Lung Cancer, Oncology, Pulmonary Diseases, Radiation Oncology
- Type of Study: Drug
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) The primary objective of this study is to assess the efficacy of durvalumab/immunotherapy with standard of care stereotactic body radiation therapy for compared to placebo with SBRT for patients with early stage lung cancer.
Criteria:
Stage I To Ii Nsclc, With Clinical Stage I/Ii Lymph Node-Negative (T1 To T3n0m0) Disease And Planned To Receive Definitive Treatment With Sbrt
Keywords:
Lung Cancer, Stereotactic Body Radiation Therapy (Sbrt), Immunotherapy
For More Information:
Dr. Emily Daugherty, Md
513-584-4073
daugheec@ucmail.uc.edu